A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)

This study is testing whether MRI-guided stereotactic ablative radiotherapy (SABR) — a highly precise form of radiation that is guided in real-time by MRI imaging — is feasible and acceptable for treating tumors in the abdomen or centrally located lung tumors. **You may be eligible if...** - You have no MRI contraindications (e.g., no metal implants that are MRI-incompatible) - You are eligible for abdominal or central lung SABR (a precise, few-session radiation treatment) according to established guidelines - You have no more than 3 sites of oligometastatic disease (a small number of cancer spread sites) - Your general health is adequate (performance status ≤2) - Your life expectancy is greater than 6 months - You are willing to attend follow-up visits for at least 1 year **You may NOT be eligible if...** - You have a contraindication to MRI - You cannot tolerate lying in an MRI machine - You have serious uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.